MINERALYS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.77 USD | +2.82% |
|
+4.67% | +48.49% |
Presenter SpeechGeoffrey Meacham (Analysts)Okay. Welcome to the last session of the BofA Healt...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Companyâs product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
12.77
USD
Average target price
33.5
USD
Spread / Average Target
+162.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +48.49% | 634M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- MLYS Stock
- News Mineralys Therapeutics, Inc.
- Transcript : Mineralys Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 05
